Merck KGaA Closes JV Deal With Biomet
Merck KGaA of Germany and Biomet, based in Indiana, USA, have announcedthat they have successfully closed the deal for their 50/50 joint venture to manufacture and distribute orthopedic products and biomaterials (Marketletter December 1, 1997), to be called Biomet-Merck.
Merck says that the formation of the JV will create a market-leading company with capability for international growth. The company went on to say that the strategic fit between its biomaterial division and Biomet's European operations is complementary in terms of product lines, geography and core competences. In particular, the agreement provides access to the all-important US market for Biomet-Merck's existing and future biomaterial products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze